Finasteride/latanoprost/minoxidil

Finasteride/latanoprost/minoxidil
Finasteride
Latanoprost (left) and minoxidil (right)
Combination of
Finasteride5α-Reductase inhibitor
LatanoprostProstaglandin F receptor agonist
MinoxidilPotassium channel opener
Clinical data
Other namesTH-07; TH07
Routes of
administration		Topical[1]
Drug classHair loss medication

Finasteride/latanoprost/minoxidil (developmental code name TH-07 or TH07) is a topical combination drug which is under development for the treatment of alopecia (hair loss).[1][2][3] It is specifically a combination of finasteride (Propecia) (0.1%), a 5α-reductase inhibitor (5α-RI); latanoprost (Xalatan) (0.03%), a prostaglandin F2α analogue and prostaglandin F receptor agonist; and minoxidil (Rogaine) (5%), a KATP potassium channel opener.[1] All three of these drugs have individually been shown to stimulate hair growth in the setting of alopecia, and both finasteride and minoxidil are approved and widely used for treatment of alopecia.[4][5][6][7] Finasteride/latanoprost/minoxidil is under development by Triple Hair.[1][2] As of December 2023, the drug is in phase 2 clinical trials.[1]

See also

References

  1. ^ a b c d e "Finasteride/latanoprost/minoxidil". AdisInsight. 19 December 2023. Retrieved 23 October 2025.
  2. ^ a b "Delving into the Latest Updates on TH-07 with Synapse". Synapse. 30 September 2025. Retrieved 23 October 2025.
  3. ^ Sekhavat H, Ford P, Lepage A, Nateghi A, Yehuda SB, Bourgeois M (2023). "TH07 - A New Novel Topical Treatment for Androgenic Alopecia". International Journal of Trichology. 15 (6): 241–247. doi:10.4103/ijt.ijt_145_22 (inactive 24 October 2025). PMC 11588191. PMID 39600423.{{cite journal}}: CS1 maint: DOI inactive as of October 2025 (link)
  4. ^ Anastassakis K (2022). "Finasteride". Androgenetic Alopecia From A to Z. Cham: Springer International Publishing. pp. 41–75. doi:10.1007/978-3-031-08057-9_2. ISBN 978-3-031-08056-2. Retrieved 23 October 2025.
  5. ^ Anastassakis K (2022). "Latanoprost". Androgenetic Alopecia From A to Z. Cham: Springer International Publishing. pp. 161–165. doi:10.1007/978-3-031-08057-9_13. ISBN 978-3-031-08056-2. Retrieved 23 October 2025.
  6. ^ Anastassakis K (2022). "Minoxidil". Androgenetic Alopecia From A to Z. Cham: Springer International Publishing. pp. 11–39. doi:10.1007/978-3-031-08057-9_1. ISBN 978-3-031-08056-2. Retrieved 23 October 2025.
  7. ^ Altendorf S, Bertolini M, Le Riche A, Tosti A, Paus R (January 2026). "Frontiers in the physiology of male pattern androgenetic alopecia: beyond the androgen horizon". Physiological Reviews. 106 (1): 121–195. doi:10.1152/physrev.00005.2024. PMID 40638068.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.